Posts Tagged ‘storm’

BrainStorm Reschedule Webcast Audio Conference

In BUSINESS OF STEM CELLS on October 15, 2009 at 12:27 pm

NEW YORK & PETACH TIKVAH, Israel–(Business Wire)– BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI – News) , announced today that it will reschedule the webcast audio conference to update shareholders on its strategy and report on the way forward towards clinical trials. This event will be rescheduled for a later date to be announced soon. We apologize for any inconvenience.

via BrainStorm Announces That It Will Reschedule Its Webcast Audio Conference | Reuters.


BrainStorm (BCLI) – Bone Marrow Stem Cell Co. Profile Released

In BUSINESS OF STEM CELLS on August 27, 2009 at 8:42 am

Bone Marrow Stem Cell Company Profile Released

LAS VEGAS, Aug. 27, 2009 (GLOBE NEWSWIRE) — A report addressing one company’s research using human bone marrow stem cells has been released. The report will explore the efforts of BrainStorm (OTCBB:BCLI) and is of interest to investors of leading stem cell equities Geron (Nasdaq:GERN), Osiris Therapeutics (Nasdaq:OSIR), Aastrom Biosciences (Nasdaq:ASTM) and StemCells (Nasdaq:STEM).

From the report: BrainStorm (OTCBB:BCLI) is a leading developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing NTF cells from the patient’s own bone marrow in order to treat, Parkinson, ALS, and Spinal Cord Injury.

The adult stem cells are used to create healthy NTF cells which produce and secrete neurotrophic factors, which are essential for the survival and outgrowth of neurons, and may become beneficial in neurodegenerative diseases. Patients treated with the Company’s NurOwn(tm) therapeutic cells are expected to enjoy a rapid recovery and much enhanced quality of life. BrainStorm’s therapy has the potential to cure underlying pathology, rather than simply treat symptoms. BrainStorm’s management and scientific teams are passionately devoted to the Company’s mission: regenerating the mind… in their lifetime.

via SmallCapSentinel.com: Bone Marrow Stem Cell Company Profile Released.


In ALL ARTICLES on August 25, 2009 at 8:22 am

— BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI | Quote | Chart | News | PowerRating) opened Monday at $0.084 per share on trading volume of 2,680,000 shares.

In a press release out on Aug 24, 2009 — BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has secured the funding required to complete pre-clinical trials underway for the treatment of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The company expects to begin Phase I clinical studies in 2010.

%d bloggers like this: